Shire's hereditary angioedema drug Takhzyro tops GoodRx's list of the most expensive drugs approved in the U.S. last year, with a list price of $573,820 per year.
GoodRx, a website and app that tracks prescription drug prices and offers coupons, used pricing and usage data from drug manufacturer websites for its list. Using the official manufacturer list price, GoodRx calculated the yearly supply of each drug at its most common dosage. It excluded drugs administered by a healthcare provider.
The 10 most expensive drugs approved in 2018 and their primary indication:
1. Takhzyro — $573,820 (Hereditary angioedema)
2. Tegsedi — $449,800 (Hereditary polyneuropathy)
3. Vitrakvi — $399,069 (Solid tumors)
4. Tibsovo — $317,733 (Acute myeloid leukemia)
5. Galafold — $315,250 (Fabry disease)
6. Symdeko — $292,000 (Cystic fibrosis)
7. Xospata — $273,750 (Acute myeloid leukemia
8. Lobrena — $195,345 (Lung cancer)
9. Palynziq — $178,120 (Phenylketonuria)
10. Talzenna — $177,390 (Breast cancer)
Access the full report here.